Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...

31.6% of people taking tirzepatide achieved at least 25% body weight loss compared to 16.1% of those receiving semaglutide, according to Lilly, which said it plans to present the data in full at a ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Zepbound led to an average weight loss of 20.2 percent compared to ... while Wegovy’s established cardiovascular data makes it a strong choice for heart health considerations,” notes Dr ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ... "I’m just not persuaded that the data on which FDA is relying ...

“Zepbound, as expected, was more effective in promoting weight loss. While Wegovy caused an average weight loss of 13.7% body weight, Zepbound promoted around 20.2% body weight loss in patients.

Study finds GLP-1 medications such as Ozempic could result in cuts to grocery spending and reductions in spending at ...

An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...